Sai Life Sciences Q2 FY27: revenue up 23% to ₹659 crore, PAT up 17% to ₹98 crore
Q2 FY27 revenue up 23% to ₹659 crore, PAT up 17% to ₹98 crore; EBITDA margin slips to 28% from 29%.
By ScoutQuest · · 1 min read
- Q2 FY27 revenue from operations
- ₹659 crore, up 23% from ₹537 crore a year earlier
- Q2 FY27 profit after tax
- ₹98 crore against ₹84 crore
- FY27 capex projection
- Rs. 1,100 to 1,300 Crores, on track
- Period
- Q2 FY27
- Positioning
- Presents itself as an integrated CRDMO providing end-to-end discovery, development and manufacturing of small molecules for global pharma and biotech, with 350+ QA/QC professionals and labs in Manchester and Boston.
📈 Q2 FY27 revenue from operations was ₹659 crore, up 23% from ₹537 crore a year earlier, and profit after tax was ₹98 crore against ₹84 crore; EBITDA of ₹187 crore carried a 28% margin, down from 29% in Q2 FY26, so the margin moved the wrong way even as revenue grew.
📈 For the half year the company reports revenue of ₹1,213 crore against ₹1,034 crore and profit after tax of ₹172 crore against ₹144 crore, up 19%; EBITDA margin for H1 FY27 was 28% versus 27% in H1 FY26.
🏭 Capex spend was ₹621 crore in 6M FY27, including ₹358 crore in Q2, and management says it is on track for its stated overall capex projection of Rs. 1,100 to 1,300 Crores; current borrowings rose to ₹418 crore at Sep 26 from ₹75 crore at Mar 26.
🔬 Management states it commenced operations with its first end-to-end integrated collaboration onboarded last quarter, expected to be fully functional in Q3, converted another large pharma relationship into a similar strategic engagement, and advanced one molecule from late phase to commercial while adding one molecule to the late phase pipeline.
Also from Sai Life Sciences
Sai Life Sciences Q2 FY27: EBITDA ₹187 crore at 28% margin, ₹621 crore capex in H1
6 Nov 2026
Board approves SMP appointments, Q2/H1 results and ESOP share allotment
5 Nov 2026
Board meeting outcome: Q2 and H1 results approved, three senior appointments, ESOP shares allotted
5 Nov 2026
More numbers
- Revenue from operations, Q2 FY27659 (₹ Cr)
- Profit after tax, Q2 FY2798 (₹ Cr)
- EBITDA, Q2 FY27187 (₹ Cr)
- Revenue YoY growth, Q2 FY2723%
- EBITDA margin, Q2 FY2728%
- Revenue from operations, H1 FY271213 (₹ Cr)
- Profit after tax, H1 FY27172 (₹ Cr)
- Capex spend, 6M FY27Rs. 621 Crores
- Current borrowings, Sep 26418 (₹ Cr)
- Current borrowings, Mar 2675 (₹ Cr)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.